

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM621544

| | |
|------------------------------|-------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | SECURITY INTEREST |
| SEQUENCE: | 1 |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|-------------------------------|----------|----------------|---------------------------------------|
| Bausch Health Ireland Limited | | 01/21/2021 | Private Unlimited Company: IRELAND |
| Solta Medical, Inc. | | 01/21/2021 | Corporation: DELAWARE |

RECEIVING PARTY DATA

| | |
|------------------------|--|
| Name: | Barclays Bank PLC, as Collateral Agent |
| Street Address: | 745 Seventh Avenue |
| City: | New York |
| State/Country: | NEW YORK |
| Postal Code: | 10019 |
| Entity Type: | Public Limited Company: ENGLAND |

PROPERTY NUMBERS Total: 13

| Property Type | Number | Word Mark |
|----------------|----------|--------------------------------------|
| Serial Number: | 90027313 | GUTHEALTHNOW |
| Serial Number: | 90015958 | VASER FACE |
| Serial Number: | 90149032 | GUTHEALTHNOW VIRTUAL CARE RESOURCES |
| Serial Number: | 90165545 | SCRIPTPLUS |
| Serial Number: | 90181914 | LUMIFY LOVERS |
| Serial Number: | 90191485 | PROJECT WATSON |
| Serial Number: | 90165240 | THE SCIENCE OF PROBIOTICS |
| Serial Number: | 90274904 | ENVIVE DAILY PROBIOTIC SUPPLEMENT |
| Serial Number: | 90218671 | SEE REWARDS |
| Serial Number: | 90261579 | 5 SYMPTOMS |
| Serial Number: | 90248971 | ARISE ORTHO-K SYSTEM |
| Serial Number: | 90292918 | CLEAR + BRILLIANT COMPLETE TREATMENT |
| Serial Number: | 90301093 | CLEAR + BRILLIANT TOUCH |

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

TRADEMARK

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-494-5225
Email: ipteam@cogencyglobal.com
Correspondent Name: Stewart Walsh
Address Line 1: 1025 Vermont Ave NW, Suite 1130
Address Line 2: COGENCY GLOBAL Inc.
Address Line 4: Washington, D.C. 20005

| | |
|--------------------------------|--------------|
| ATTORNEY DOCKET NUMBER: | 1318307 TM 1 |
|--------------------------------|--------------|

| | |
|---------------------------|-----------|
| NAME OF SUBMITTER: | Wenny Zhu |
|---------------------------|-----------|

| | |
|-------------------|-------------|
| SIGNATURE: | /Wenny Zhu/ |
|-------------------|-------------|

| | |
|---------------------|------------|
| DATE SIGNED: | 01/21/2021 |
|---------------------|------------|

Total Attachments: 8

source=1 Trademark Security Agreement - Barclays Q3#page3.tif
source=1 Trademark Security Agreement - Barclays Q3#page4.tif
source=1 Trademark Security Agreement - Barclays Q3#page5.tif
source=1 Trademark Security Agreement - Barclays Q3#page6.tif
source=1 Trademark Security Agreement - Barclays Q3#page7.tif
source=1 Trademark Security Agreement - Barclays Q3#page8.tif
source=1 Trademark Security Agreement - Barclays Q3#page9.tif
source=1 Trademark Security Agreement - Barclays Q3#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of January 21, 2021, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and Barclays Bank PLC (“**Barclays**”), as collateral agent (in such capacity, the “**Collateral Agent**”) for the Secured Parties.

Reference is made to that certain Third Amended and Restated Pledge and Security Agreement, dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “**Security Agreement**”), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers subject to the terms and conditions set forth in that certain Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “**Credit Agreement**”), by and among Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc., the “**Parent**”), Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International, and, together with the Parent, the “**Borrowers**”), certain subsidiaries of the Parent, as subsidiary guarantors, the Lenders from time to time party thereto (the “**Lenders**”), and Barclays, in its capacities as the Swingline Lender and as Administrative Agent for the Lenders. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.3 of the Security Agreement, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:

1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
2. all goodwill associated with or symbolized by the Trademarks;
3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
4. all proceeds of and rights associated with the foregoing;

B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

2. the right to sue third parties for past, present and future infringements of any Patent; and
3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.


SECTION 3. **Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 4. **Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.


SECTION 5. **Counterparts.** This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]


BAUSCH HEALTH IRELAND LIMITED

By: 
Name: William N. Woodfield
Title: Director


BAUSCH & LOMB INCORPORATED

By: 
Name: William N. Woodfield
Title: Vice President, Treasurer

SOLTA MEDICAL, INC.

By: 
Name: William N. Woodfield
Title: Vice President, Treasurer

SALIX PHARMACEUTICALS, INC.

By: 
Name: William N. Woodfield
Title: Vice President, Treasurer

Accepted and Agreed:

BARCLAYS BANK PLC,
as Collateral Agent

By:

DocuSigned by:
Robert Walsh
FCDAF84E50AA411...

Name: Robert Walsh
Title: Assistant Vice President

[Signature Page to IPSA – Barclays]

TRADEMARK
REEL: 007166 FRAME: 0543

Schedule I - Trademark Collateral

| Current Owner on TMO Records | Mark Name | Current Application Number | Current Registration Number |
|-------------------------------------|--------------------------------------|-----------------------------------|------------------------------------|
| BAUSCH HEALTH IRELAND LIMITED | GUTHEALTHNOW | 90027313 | |
| SOLTA MEDICAL, INC. | VASER FACE | 90015958 | |
| BAUSCH HEALTH IRELAND LIMITED | GUTHEALTHNOW VIRTUAL CARE RESOURCES | 90149032 | |
| BAUSCH HEALTH IRELAND LIMITED | SCRIPTPLUS | 90165545 | |
| BAUSCH & LOMB INCORPORATED | LUMIFY LOVERS | 90181914 | |
| BAUSCH HEALTH IRELAND LIMITED | PROJECT WATSON | 90191485 | |
| BAUSCH HEALTH IRELAND LIMITED | THE SCIENCE OF PROBIOTICS | 90165240 | |
| BAUSCH HEALTH IRELAND LIMITED | ENVIVE DAILY PROBIOTIC SUPPLEMENT | 90274904 | |
| BAUSCH HEALTH IRELAND LIMITED | SEE REWARDS | 90218671 | |
| BAUSCH HEALTH IRELAND LIMITED | 5 SYMPTOMS | 90261579 | |
| BAUSCH HEALTH IRELAND LIMITED | ARISE ORTHO-K SYSTEMS | 90248971 | |
| SOLTA MEDICAL, INC. | CLEAR + BRILLIANT COMPLETE TREATMENT | 90292918 | |
| SOLTA MEDICAL, INC. | CLEAR + BRILLIANT TOUCH | 90301093 | |

Schedule II – Patent Collateral

| Appl. No. | Publ. No. | Patent No. | Title | Current PTO Owner |
|------------------|--------------------|-------------------|---|-------------------------------|
| 63/044450 | | | TARGETED RELEASE RIFAXIMIN COMPOSITIONS | BAUSCH HEALTH IRELAND LIMITED |
| 63/059395 | | | LID WIPE FORMULATIONS AND METHODS | BAUSCH HEALTH IRELAND LIMITED |
| 63/044447 | | | RIFAXIMIN LIQUID FORMULATIONS | BAUSCH HEALTH IRELAND LIMITED |
| 16/913255 | US-2020-0323627-A1 | | INTRAOCULAR LENS INJECTOR ASSEMBLY HAVING SHUTTLE ASSEMBLY RETAINING INTRAOCULAR LENS IN STORAGE VIAL AND OPERABLY PRESENTING INTRAOCULAR LENS IN INJECTOR ASSEMBLY | BAUSCH & LOMB INCORPORATED |
| 63/045596 | | | COMPOSITIONS AND METHODS FOR EYE HEALTH COMPRISING AREDS AND VITAMIN B COMPLEX | BAUSCH HEALTH IRELAND LIMITED |
| 63/045609 | | | COMPOSITIONS AND METHODS FOR EYE HEALTH COMPRISING VERY LONG CHAIN FATTY ACIDS | BAUSCH HEALTH IRELAND LIMITED |
| 63/045624 | | | COMPOSITIONS AND METHODS FOR EYE HEALTH COMPRISING LUTEIN AND ZEAXANTHIN PARTICLES | BAUSCH HEALTH IRELAND LIMITED |
| 63/045585 | | | COMPOSITIONS AND METHODS FOR AGE RELATED EYE DISEASES COMPRISING HIGH CONCENTRATIONS OF VITAMINS | BAUSCH HEALTH IRELAND LIMITED |
| 16/916421 | | | FORMULATIONS OF RIFAXIMIN AND USES THEREOF | BAUSCH HEALTH IRELAND LIMITED |
| 16/919671 | | | TRANSDUCER CARTRIDGE FOR AN ULTRASOUND THERAPY HEAD | SOLTA MEDICAL, INC. |

| Appl. No. | Publ. No. | Patent No. | Title | Current PTO Owner |
|-----------|--------------|------------|---|-------------------------------|
| 16/944956 | | | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | SALIX PHARMACEUTICALS, INC. |
| 16/945067 | | | TOPICAL COMPOSITIONS | BAUSCH HEALTH IRELAND LIMITED |
| 16/983267 | | | AQUEOUS LIQUID COMPOSITION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID | BAUSCH & LOMB INCORPORATED |
| 63/076961 | | | COMBINATIONS OF RIFAXIMIN AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER | BAUSCH HEALTH IRELAND LIMITED |
| 63/082155 | | | METHODS OF USING SOLUBLE SOLID DISPERSIONS OF RIFAXIMIN | BAUSCH HEALTH IRELAND LIMITED |
| 16/069313 | 2019-0030116 | 10653744 | FORMULATIONS AND METHODS FOR TREATING ULCERATIVE COLITIS | BAUSCH HEALTH IRELAND LIMITED |
| 16/108942 | 2019-0307716 | 10653656 | TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATING SKIN CONDITIONS | BAUSCH HEALTH IRELAND LIMITED |
| 16/893651 | 2020-0368213 | | METHODS OF TREATING HEPATIC ENCEPHALOPATHY | SALIX PHARMACEUTICALS, INC. |
| 13/790774 | 2013-0190661 | 10010722 | TRANSDUCER CARTRIDGE FOR AN ULTRASOUND THERAPY HEAD | SOLTA MEDICAL, INC. |

None.

Schedule III - Copyright Collateral